

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8395993

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
THERAGENICS CORPORATION	01/22/2024
RECEIVING PARTY DATA	
Name:	WINGSPIRE CAPITAL LLC
Street Address:	13010 MORRIS ROAD
City:	ALPHARETTA
State/Country:	GEORGIA
Postal Code:	30004
PROPERTY NUMBERS Total: 10	
Property Type	Number
Patent Number:	10189773
Patent Number:	10227289
Patent Number:	10111985
Patent Number:	9072809
Patent Number:	8987339
Patent Number:	9149560
Patent Number:	9623144
Patent Number:	10507262
Patent Number:	11083821
Patent Number:	11596710
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6785532204
Email:	Michelle.thompson@gtlaw.com
Correspondent Name:	MICHELLE THOMPSON
Address Line 1:	3333 PIEDMONT ROAD NE, ST. 2500
Address Line 4:	ATLANTA, GEORGIA 30305
ATTORNEY DOCKET NUMBER:	188041.0101600

NAME OF SUBMITTER:	MICHELLE THOMPSON
SIGNATURE:	/Michelle Thompson/
DATE SIGNED:	01/23/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 8

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page1.tif

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page2.tif

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page3.tif

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page4.tif

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page5.tif

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page6.tif

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page7.tif

source=THERAGENICS PATENT SECURITY AGREEMENT (Executed 2024.01.22)#page8.tif

PATENT SECURITY AGREEMENT

PATENT SECURITY AGREEMENT, dated as of January 22, 2024 (as the same may be amended, restated, supplemented, or otherwise modified from time to time, this “Agreement”), between Theragenics Corporation, a Delaware corporation (“Grantor”), and WINGSPIRE CAPITAL LLC, as Administrative Agent (in such capacity, the “Administrative Agent”).

Reference is made to (a) the Credit Agreement, dated as of October 14, 2021, by and among JUNIPER HOLDINGS, INC., a Delaware corporation (“Holdings”), THERAGENICS CORPORATION, a Delaware corporation (the “Company”), the Subsidiaries of the Company from time to time party thereto as “Borrowers” (the Company, together with such subsidiaries each, a “Borrower” and individually and collectively, jointly and severally, the “Borrowers”), the Subsidiaries of the Company from time to time party thereto as Guarantors (Holdings, together with such subsidiaries, each, a “Guarantor” and collectively, the “Guarantors”), the financial institutions from time to time party thereto as lenders (each, a “Lender” and, collectively, the “Lenders”), and the Administrative Agent (as the same may be amended, restated, supplemented, or otherwise modified from time to time, the “Credit Agreement”), and (b) the Pledge and Security Agreement, dated as of October 14, 2021, by and among the Borrowers, the Guarantors, and the Administrative Agent (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”).

The Lenders have agreed to extend credit to the Borrowers subject to the terms and conditions set forth in the Credit Agreement, the Guarantors have guaranteed Obligations and the Grantor, among others, has secured its obligations pursuant to the Security Agreement. The obligations of the Lenders to extend such credit are conditioned upon, among other things, the execution and delivery of this Agreement.

Accordingly, the parties hereto agree as follows:

1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement or the Credit Agreement.

2. **Grant of Security Interest.** As security for the payment or performance, as applicable, in full when due (whether at the stated maturity, by acceleration or otherwise) of the Obligations, Grantor, pursuant to the Security Agreement, did and hereby does grant to the Administrative Agent (and its successors and assigns), for the ratable benefit of the Secured Parties, a security interest in, all Grantor’s right, title and interest in, to or under any and all of the following assets now owned or at any time hereafter acquired (collectively, the “Patent Collateral”):

(a) all letters patent, including letters patent of the United States of America, all registrations and recordings thereof and all applications for letters patent, including registrations, recordings and pending applications in the United States Patent and Trademark Office, in each case described on Schedule I and all reissues, renewals, continuations and extensions thereof and amendments thereto (the “Patents”);

(b) all inventions and improvements described and claimed therein, including the right to make, use and/or sell the inventions disclosed or claimed therein,

(c) all reissues, continuations, divisions, continuations in part, renewals or extensions thereof and amendments thereto, and the inventions disclosed or claimed therein, and

(d) all income, fees, royalties, damages, claims and payments now or hereafter due and/or payable thereunder and with respect thereto.

3. Security Agreement. The security interests granted to the Administrative Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Administrative Agent pursuant to the Security Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of the Administrative Agent with respect to the Patent Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.


4. Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or in electronic (e.g., "pdf" or "tif") format shall be effective as delivery of a manually executed counterpart of this Agreement.

5. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

[Continued on the following page.]

IN WITNESS WHEREOF, the parties hereto have duly executed this Patent Security Agreement
as of the day and year first above written.

Theragenics Corporation


By:  _____

Name: Mark Pugh

Title: President and CEO

[THERAGENICS---PATENT SECURITY AGREEMENT]

WINGSPIRE CAPITAL LLC, as Administrative
Agent

By: 
Name: Christopher J. Coutu
Title: Senior Managing Director

[THERAGENICS---PATENT SECURITY AGREEMENT]

PATENT
REEL: 066211 FRAME: 0721

SCHEDULE I

PATENTS

Owner	Title	Juris-diction	Application No.	File Date	Patent No.
Theragenics Corporation	IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION	US	13/696032	1/15/2013	10189773
Theragenics Corporation	METHODS FOR TREATING DISEASES OF THE LUNG	US	13/696028	1/16/2013	10227289
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER FORMULATIONS FOR THE CONTROLLED DELIVERY OF BIOMOLECULES	US	13/571116	8/9/2012	10111985
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	US	14/273408	5/8/2014	9072809
Theragenics Corporation	SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION	US	14/212457	3/14/2014	8987339
Theragenics Corporation	SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION	US	14/618804	2/10/2015	9149560
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	US	14/722829	5/27/2015	9623144
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	US	15/467019	3/23/2017	10507262
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER FORMULATIONS FOR THE	US	16/146150	9/28/2018	11083821

	CONTROLLED DELIVERY OF BIOMOLECULES				
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	US	16/705811	12/6/2019	11596710
Theragenics Corporation	COMPOSITIONS AND METHODS FOR TREATING WOUNDS	US	17/312596	6/10/2021	Pending
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	US	18/152,430	01/10/2023	Pending
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	Europe	13787696.7	5/10/2013	EP2846847
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	United Kingdom	13787696.7	5/10/2013	EP2846847
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	France	13787696.7	5/10/2013	EP2846847
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	Ireland	13787696.7	5/10/2013	EP2846847
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	Germany	13787696.7	5/10/2013	EP2846847
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	Japan	2015-511774	5/10/2013	6206987
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	China	2.0138E+11	5/10/2013	ZL201380037 109.6
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR	Canada	2873105	5/10/2013	CA 2873105

	RETINAL DETACHMENT				
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT	Australia	2013259166	5/10/2013	AU 2013259166
Theragenics Corporation	SOLID POLYGLYCOL- BASED BIOCOMPATIBLE PRE- FORMULATION	Europe	14770108	3/14/2014	Pending
Theragenics Corporation	SOLID POLYGLYCOL- BASED BIOCOMPATIBLE PRE- FORMULATION	Japan	2016-502849	3/14/2014	JP 6516721
Theragenics Corporation	SOLID POLYGLYCOL- BASED BIOCOMPATIBLE PRE- FORMULATION	China	2.0148E+11	3/14/2014	Pending
Theragenics Corporation	SOLID POLYGLYCOL- BASED BIOCOMPATIBLE PRE- FORMULATION	Canada	2903823	3/14/2014	CA2903823
Theragenics Corporation	SOLID POLYGLYCOL- BASED BIOCOMPATIBLE PRE- FORMULATION	Australia	2014236351	3/14/2014	AU 2014236351
Theragenics Corporation	SOLID POLYGLYCOL- BASED BIOCOMPATIBLE PRE- FORMULATION	Hong Kong	16107536.8	3/14/2014	Pending
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	Europe	14770805.1	3/14/2014	EP 2968131
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	United Kingdom	14770805.1	3/14/2014	EP 2968131

Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	Germany	14770805.1	3/14/2014	EP 2968131
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	France	14770805.1	3/14/2014	EP 2968131
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	Ireland	14770805.1	3/14/2014	EP 2968131
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	Japan	2016-502902	3/14/2014	JP 6525952
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	China	2.0148E+11	3/14/2014	CN 2014800276626
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	Canada	2903829	3/14/2014	CA2903829
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	Australia	2014236385	3/14/2014	AU 2014236385
Theragenics Corporation	BIOCOMPATIBLE HYDROGEL POLYMER MATRIX FOR DELIVERY OF CELLS	Hong Kong	16107544.8	3/14/2014	HK1219430